Revolution Medicines Inc (RVMD)

$58.58

-0.05

(-0.09%)▲

Market is closed - opens 8 PM, 29 Nov 2024

Performance

  • $57.45
    $59.21
    $58.58
    downward going graph

    1.93%

    Downside

    Day's Volatility :2.96%

    Upside

    1.06%

    downward going graph
  • $21.18
    $62.40
    $58.58
    downward going graph

    63.84%

    Downside

    52 Weeks Volatility :66.06%

    Upside

    6.12%

    downward going graph

Returns

PeriodRevolution Medicines IncSector (Health Care)Index (Russel 2000)
3 Months
34.5%
-6.1%
0.0%
6 Months
54.7%
1.2%
0.0%
1 Year
170.31%
12.2%
0.0%
3 Years
119.59%
10.8%
-21.2%

Highlights

Market Capitalization
9.7B
Book Value
$9.34
Earnings Per Share (EPS)
-3.71
Wall Street Target Price
71.429
Profit Margin
0.0%
Operating Margin TTM
-84595.28%
Return On Assets TTM
-28.56%
Return On Equity TTM
-47.18%
Revenue TTM
742.0K
Revenue Per Share TTM
0.01
Quarterly Revenue Growth YOY
-95.19999999999999%
Gross Profit TTM
-217.7M
EBITDA
-621.6M
Diluted Eps TTM
-3.71
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-3.45
EPS Estimate Next Year
-3.98
EPS Estimate Current Quarter
-0.89
EPS Estimate Next Quarter
-0.97

Analyst Recommendation

Buy
    94%Buy
    5%Hold
    0
    0%Sell
Based on 19 Wall street analysts offering stock ratings for Revolution Medicines Inc(by analysts ranked 0 to 5 stars)
Based on 19 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
18
18
16
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 21.93%

Current $58.58
Target $71.43

Technicals Summary

Sell

Neutral

Buy

Revolution Medicines Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Revolution Medicines Inc
Revolution Medicines Inc
22.79%
54.7%
170.31%
119.59%
102.87%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-18.91%
-22.62%
-5.64%
15.07%
102.66%
Biontech Se
Biontech Se
4.66%
25.97%
22.38%
-67.3%
441.77%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
-11.7%
68.83%
59.14%
40.17%
115.51%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-1.95%
4.52%
33.38%
145.68%
112.25%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Revolution Medicines Inc
Revolution Medicines Inc
NA
NA
NA
-3.45
-0.47
-0.29
NA
9.34
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
18.25
18.25
1.1
44.91
0.17
0.07
NA
272.04
Biontech Se
Biontech Se
160.8
NA
0.04
-3.04
-0.02
-0.01
NA
79.73
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-0.17
-15.01
-0.03
NA
0.25
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
1.21
0.54
-0.03
0.12
NA
60.65
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Revolution Medicines Inc
Revolution Medicines Inc
Buy
$9.7B
102.87%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$81.1B
102.66%
18.25
33.61%
Biontech Se
Biontech Se
Buy
$27.1B
441.77%
160.8
-15.36%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$31.6B
115.51%
NA
-15.86%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$118.9B
112.25%
32.84
-4.51%

Insights on Revolution Medicines Inc

  • Decreasing Revenue

    Revenue is down for the last 4 quarters, 15.33M → 742.0K (in $), with an average decrease of 60.1% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, -116.00M → -156.28M (in $), with an average decrease of 16.1% per quarter

Institutional Holdings

  • Vanguard Group Inc

    8.89%

  • Wellington Management Company LLP

    8.14%

  • BlackRock Inc

    7.99%

  • Farallon Capital Management, L.L.C.

    6.75%

  • Baker Bros Advisors LP

    4.51%

  • Nextech Invest AG

    3.75%

Corporate Announcements

  • Revolution Medicines Inc Earnings

    Revolution Medicines Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

revolution medicines discovers and develops new drugs that harness the therapeutic potential of frontier oncology targets on behalf of cancer patients. our innovative product engine draws inspiration from nature and evolution, which offer insights into cancer targets, disease mechanisms and therapeutic approaches. we pay particular attention to natural products that are inherently rich with biological function as a result of natural selection and can inform and guide our discovery and development of small molecules that can modulate these targets.

Organization
Revolution Medicines Inc
Employees
490
CEO
Dr. Mark A. Goldsmith Ph.D.
Industry
Health Technology

FAQs